FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100676105> ?p ?o ?g. }

• W3100676105 endingPage "777" @default.
• W3100676105 startingPage "768" @default.
• W3100676105 abstract "Abstract Background Data relating to the efficacy of immune checkpoint inhibitors (ICI) for salivary gland carcinomas (SGC) is gradually evolving with responses varying among different histotypes. To address these disparities, this retrospective analysis examined the prevalence of recognized biomarkers of response to ICI; namely programmed death‐1 (PD‐1), programmed death‐ligand 1 (PD‐L1), combined positive score (CPS), epidermal growth factor receptor (EGFR), and microsatellite instability (MSI) in patients with SGC with an aim to determine any prognostic or survival benefits and stratify the use of ICI in this disease. Patients and methods Of 52 patients with primary SGC eligible for this study, the most common histological types were adenoid cystic carcinoma (n = 17, 33%), salivary duct carcinoma (n = 14, 27%), mucoepidermoid carcinoma (n = 11, 21%), and acinic cell carcinoma (n = 6, 11%). Immunohistochemistry (IHC) was performed using the Ventana Discovery Ultra auto‐staining platform for EGFR, PD‐1, PD‐L1, and mismatch repair (MMR) proteins. CPS ≥1 defined PD‐L1 positive cases and log‐rank testing was performed to examine the relationship between PD‐L1 expression status and disease‐free survival (DFS) and overall survival (OS). Results CPS positivity was seen in 9 (17.3%) patients, none of which were adenoid cystic carcinoma. All 52 (100%) cases expressed retained MMR proteins inferring microsatellite stability (MSS) and EGFR expression was identified in 45 of 52 (86.5%) patients. CPS positivity (score ≥1) was significantly associated with advanced pathological T status ( P = .021), advanced pathological N status ( P = .006), high histological tumor grade ( P = .045), and positive histological margin ( P = .023). Patients with PD‐L1 positivity in tumor cells did not have an inferior 3‐year OS ( P = .93). Conclusion The data from this retrospective study highlighting the uniform microsatellite stability alongside the low prevalence of CPS positivity suggests that only a minority of SGC patients may benefit from ICI therapy alone. The high rates of EGFR expression in SGC may be a target to augment immune checkpoint therapy response." @default.
• W3100676105 created "2020-11-23" @default.
• W3100676105 creator A5003427020 @default.
• W3100676105 creator A5005373482 @default.
• W3100676105 creator A5017925841 @default.
• W3100676105 creator A5018633341 @default.
• W3100676105 creator A5025328738 @default.
• W3100676105 creator A5041888746 @default.
• W3100676105 creator A5053835464 @default.
• W3100676105 creator A5075421889 @default.
• W3100676105 creator A5087567409 @default.
• W3100676105 date "2020-11-09" @default.
• W3100676105 modified "2023-10-12" @default.
• W3100676105 title "Therapeutic implications of immune‐profiling and <scp>EGFR</scp> expression in salivary gland carcinoma" @default.
• W3100676105 cites W1564699296 @default.
• W3100676105 cites W1964285802 @default.
• W3100676105 cites W1977258080 @default.
• W3100676105 cites W1994890851 @default.
• W3100676105 cites W2005621869 @default.
• W3100676105 cites W2026601125 @default.
• W3100676105 cites W2036785342 @default.
• W3100676105 cites W2051574869 @default.
• W3100676105 cites W2072546233 @default.
• W3100676105 cites W2072562385 @default.
• W3100676105 cites W2087861588 @default.
• W3100676105 cites W2098523473 @default.
• W3100676105 cites W2111109297 @default.
• W3100676105 cites W2141471081 @default.
• W3100676105 cites W2144909477 @default.
• W3100676105 cites W2338774035 @default.
• W3100676105 cites W2343095226 @default.
• W3100676105 cites W2369087270 @default.
• W3100676105 cites W2431949017 @default.
• W3100676105 cites W2596539906 @default.
• W3100676105 cites W2606367731 @default.
• W3100676105 cites W2733051925 @default.
• W3100676105 cites W2768318314 @default.
• W3100676105 cites W2792603138 @default.
• W3100676105 cites W2799372507 @default.
• W3100676105 cites W2801120517 @default.
• W3100676105 cites W2801828337 @default.
• W3100676105 cites W2884883038 @default.
• W3100676105 cites W2903493423 @default.
• W3100676105 cites W2913541732 @default.
• W3100676105 cites W2946611948 @default.
• W3100676105 cites W2947026438 @default.
• W3100676105 cites W2954681469 @default.
• W3100676105 cites W3006241692 @default.
• W3100676105 cites W3010469101 @default.
• W3100676105 doi "https://doi.org/10.1002/hed.26529" @default.
• W3100676105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33169486" @default.
• W3100676105 hasPublicationYear "2020" @default.
• W3100676105 type Work @default.
• W3100676105 sameAs 3100676105 @default.
• W3100676105 citedByCount "10" @default.
• W3100676105 countsByYear W31006761052021 @default.
• W3100676105 countsByYear W31006761052022 @default.
• W3100676105 countsByYear W31006761052023 @default.
• W3100676105 crossrefType "journal-article" @default.
• W3100676105 hasAuthorship W3100676105A5003427020 @default.
• W3100676105 hasAuthorship W3100676105A5005373482 @default.
• W3100676105 hasAuthorship W3100676105A5017925841 @default.
• W3100676105 hasAuthorship W3100676105A5018633341 @default.
• W3100676105 hasAuthorship W3100676105A5025328738 @default.
• W3100676105 hasAuthorship W3100676105A5041888746 @default.
• W3100676105 hasAuthorship W3100676105A5053835464 @default.
• W3100676105 hasAuthorship W3100676105A5075421889 @default.
• W3100676105 hasAuthorship W3100676105A5087567409 @default.
• W3100676105 hasConcept C104317684 @default.
• W3100676105 hasConcept C126322002 @default.
• W3100676105 hasConcept C142724271 @default.
• W3100676105 hasConcept C143998085 @default.
• W3100676105 hasConcept C180754005 @default.
• W3100676105 hasConcept C204232928 @default.
• W3100676105 hasConcept C207886595 @default.
• W3100676105 hasConcept C2777546739 @default.
• W3100676105 hasConcept C2778039489 @default.
• W3100676105 hasConcept C2778937882 @default.
• W3100676105 hasConcept C2779231225 @default.
• W3100676105 hasConcept C2779767149 @default.
• W3100676105 hasConcept C2780329156 @default.
• W3100676105 hasConcept C2780859518 @default.
• W3100676105 hasConcept C2781066530 @default.
• W3100676105 hasConcept C55493867 @default.
• W3100676105 hasConcept C61320498 @default.
• W3100676105 hasConcept C71924100 @default.
• W3100676105 hasConcept C86803240 @default.
• W3100676105 hasConceptScore W3100676105C104317684 @default.
• W3100676105 hasConceptScore W3100676105C126322002 @default.
• W3100676105 hasConceptScore W3100676105C142724271 @default.
• W3100676105 hasConceptScore W3100676105C143998085 @default.
• W3100676105 hasConceptScore W3100676105C180754005 @default.
• W3100676105 hasConceptScore W3100676105C204232928 @default.
• W3100676105 hasConceptScore W3100676105C207886595 @default.
• W3100676105 hasConceptScore W3100676105C2777546739 @default.
• W3100676105 hasConceptScore W3100676105C2778039489 @default.
• W3100676105 hasConceptScore W3100676105C2778937882 @default.
• W3100676105 hasConceptScore W3100676105C2779231225 @default.

• next